首页|免疫相关不良事件热点问题解析

免疫相关不良事件热点问题解析

扫码查看
原文链接
  • 万方数据
  • 维普
以免疫检查点抑制剂(ICIs)为代表的免疫治疗在给恶性肿瘤患者带来良好疗效的同时,也可能会导致免疫相关不良事件(irAEs).已有较多的国内外指南或共识指导临床医师有效解决绝大多数irAEs.然而irAEs的定义和判定、时间规律、个体差异、激素和免疫抑制剂使用、irAEs与疗效的关系、免疫重启、特殊人群等问题仍有待进一步探讨,重症型、难治性和多重irAEs的识别和处理仍待进一步解决.本文梳理了irAEs的十个热点问题并逐一进行解析,以期给临床医师带来帮助.
Clarification of Hot Issues of Immune-Related Adverse Events
Immunotherapy,represented by immune checkpoint inhibitors,may lead to immune-related adverse events(irAEs)while demonstrating favorable efficacy in patients with malignant tumors.Many domestic and international guidelines or consensus have been established to assist clinicians in effectively managing the majority of irAEs.However,further exploration about irAEs is required regarding the definition and determination,temporal patterns,individual variances,utilization of hormones and immunosuppressants,correlation between irAEs and therapeutic outcomes,immune reactivation,and special populations.The identification and management of severe,refractory,and multiple irAEs necessitate additional solutions.This paper aims to clarify 10 prominent issues concerning irAEs individually and provide assistance for clinicians.

Immune checkpoint inhibitorsImmune-related adverse eventsClarification

付烊、王俊、章必成

展开 >

441001 襄阳,湖北中医药大学附属襄阳医院肿瘤血液科

250014 济南,山东第一医科大学第一附属医院肿瘤科

430060 武汉,武汉大学人民医院肿瘤中心

免疫检查点抑制剂 免疫相关不良事件 解析

Hubei Provincial Clinical Medical Research Center of Integrative Chinese and Western Medicine for Green Tumor TreatmentNational Famous Old Expert of Chinese Medicine,Professor Zhu Xueming Inheritance Office国家自然科学基金湖北省中西医结合肿瘤绿色治疗临床医学研究中心全国名老中医药专家朱学明教授传承工作室湖北省医学青年拔尖人才项目襄阳市科技研究与开发项目希思科-BMS肿瘤免疫治疗研究基金武汉市科技局知识创新项目

20214620227582272928鄂科技函社202146号国中医药人教发202275号EWT2019-482022YL39AY-BMS2019-0032022020801010475

2024

10.3971/j.issn.1000-8578.2024.24.0522

肿瘤防治研究
湖北省卫生厅,中国抗癌协会,湖北省肿瘤医院

肿瘤防治研究

CSTPCD
影响因子：0.737
ISSN：1000-8578
年,卷(期)：2024.51(9)